Patients with highly unstable type 1 diabetes eligible for islet transplantation can be managed with a closed-loop insulin delivery system: A series of N-of-1 randomized controlled trials.
artificial pancreas, brittle diabetes, closed-loop, hypoglycaemia unawareness, problematic hypoglycaemia, severe hypoglycaemia, type 1 diabetes, unstable diabetes
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
16
07
2020
revised:
24
09
2020
accepted:
26
09
2020
pubmed:
2
10
2020
medline:
6
7
2021
entrez:
1
10
2020
Statut:
ppublish
Résumé
To compare the efficacy of the closed-loop Diabeloop for highly unstable diabetes (DBLHU) system with the open-loop predictive low glucose suspend (PLGS) system in patients with highly unstable type 1 diabetes (T1D) who experience acute metabolic events. DBLHU-WP10 was an interventional, controlled, randomized, open-label study that comprised two cycles of N-of-1 trials (2-of-1 trials). Each trial consisted of two crossover 4-week periods of treatment with either DBLHU or PLGS in randomized order. The primary outcome was the percentage of time spent in the 70-180 mg/dL glucose range (time in range [TIR]). Five out of seven randomized patients completed the aggregated 2-of-1 trials. TIR was significantly higher with DBLHU (73.3% ± 1.7%) compared with PLGS (43.5% ± 1.7%; P < .0001). The percentage of time below 70 mg/dL was significantly lower with DBLHU (0.9% ± 0.4%) versus PLGS (3.7% ± 0.4%; P < .0001). DBLHU was also significantly superior to PLGS in reducing hyperglycaemic excursions and improving almost all other secondary outcomes, including glucose variability and satisfaction score. No adverse event could be related to the experimental treatment. DBLHU was superior to PLGS in improving the metabolic control of patients with highly unstable T1D who require an islet or pancreas transplant but who either have a contraindication or refuse to consent.
Substances chimiques
Blood Glucose
0
Hypoglycemic Agents
0
Insulin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
186-194Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Tattersall RB. Brittle diabetes revisited: the third Arnold Bloom memorial lecture. Diabetes Med. 1997;14:99-110.
Choudhary P, Rickels MR, Senior PA, et al. Evidence-informed clinical practice recommendations for treatment of type 1 diabetes complicated by problematic hypoglycemia. Diabetes Care. 2015;38:1016-1029.
Gill GV, Lucas S, Kent LA. Prevalence and characteristics of brittle diabetes in Britain. QJM. 1996;89:839-843.
Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343:230-238.
Byrne ML, Hopkins D, Littlejohn W, et al. Outcomes for adults with type 1 diabetes referred with severe hypoglycaemia and/or referred for islet transplantation to a specialist hypoglycaemia service. Horm Metab Res. 2015;47:9-15.
Little SA, Speight J, Leelarathna L, et al. Sustained reduction in severe hypoglycemia in adults with type 1 diabetes complicated by impaired awareness of hypoglycemia: two-year follow-up in the hypocompass randomised clinical trial. Diabetes Care. 2018;41:1600-1607.
Heinemann L, Freckmann G, Ehrmann D, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (hypode): a multicentre, randomised controlled trial. Lancet. 2018;391:1367-1377.
Bosi E, Choudhary P, de Valk HW, et al. Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (smile): an open-label randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7:462-472.
Lablanche S, Vantyghem MC, Kessler L, et al. Islet transplantation versus insulin therapy in patients with type 1 diabetes with severe hypoglycaemia or poorly controlled glycaemia after kidney transplantation (trimeco): a multicentre, randomised controlled trial. Lancet Diabetes Endocrinol. 2018;6:527-537.
Benhamou PY, Franc S, Reznik Y, et al. Closed loop insulin delivery in adults with type 1 diabetes in real life conditions: a multicentre, 12-week randomised crossover trial. Lancet Digital Health. 2019;1:e17-e25.
Hanaire H, Franc S, Borot S, et al. Efficacy of the diabeloop closed-loop system to improve glycaemic control in patients with type 1 diabetes exposed to gastronomic dinners or to sustained physical exercise. Diabetes Obes Metab. 2020;22:324-334.
Vantyghem MC, Hazzan M, Tourvieille S, et al. Selection of diabetic patients for islet transplantation. A single-center experience. Diabetes Metab. 2004;30:417-423.
Nikles J, Mitchell GK, Schluter P, et al. Aggregating single patient (n-of-1) trials in populations where recruitment and retention was difficult: the case of palliative care. J Clin Epidemiol. 2011;64:471-480.
Vohra S, Shamseer L, Sampson M, et al. Consort extension for reporting n-of-1 trials (cent) 2015 statement. BMJ. 2015;350:h1738.
Nathan DM, Kuenen J, Borg R, et al. Translating the a1c assay into estimated average glucose values. Diabetes Care. 2008;31:1473-1478.
Bergenstal RM, Beck RW, Close KL, et al. Glucose management indicator (GMI): a new term for estimating A1c from continuous glucose monitoring. Diabetes Care. 2018;41:2275-2280.
Monnier L, Colette C, Wojtusciszyn A, et al. Toward defining the threshold between low and high glucose variability in diabetes. Diabetes Care. 2017;40:832-838.
Kovatchev BP, Cox DJ, Gonder-Frederick LA, Young-Hyman D, Schlundt D, Clarke W. Assessment of risk for severe hypoglycemia among adults with iddm: validation of the low blood glucose index. Diabetes Care. 1998;21:1870-1875.
Service FJ, Molnar GD, Rosevear JW, et al. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes. 1970;19:644-655.
Saisho Y. Use of diabetes treatment satisfaction questionnaire in diabetes care: importance of patient-reported outcomes. Int J Environ Res Public Health. 2018;15(5):947.
IHSG. International hypoglycaemia study group. Glucose concentrations of less than 3.0 mmol/l (54 mg/dl) should be reported in clinical trials: a joint position statement of the american diabetes association and the european association for the study of diabetes. Diabetes Care. 2017;40:155-157.
Anderson SM, Buckingham BA, Breton MD, et al. Hybrid closed-loop control is safe and effective for people with type 1 diabetes who are at moderate to high risk for hypoglycemia. Diabetes Technol Ther. 2019;21:356-363.
Abitbol A, Rabasa-Lhoret R, Messier V, et al. Overnight glucose control with dual- and single-hormone artificial pancreas in type 1 diabetes with hypoglycemia unawareness: a randomised controlled trial. Diabetes Technol Ther. 2018;20:189-196.
Gruessner AC, Gruessner RW. Long-term outcome after pancreas transplantation: a registry analysis. Curr Opin Organ Transplant. 2016;21:377-385.
Lablanche S, Borot S, Wojtusciszyn A, et al. Five-year metabolic, functional, and safety results of patients with type 1 diabetes transplanted with allogenic islets within the Swiss-French gragil network. Diabetes Care. 2015;38:1714-1722.
Vantyghem MC, Chetboun M, Gmyr V, et al. Ten-year outcome of islet alone or islet after kidney transplantation in type 1 diabetes: a prospective parallel-arm cohort study. Diabetes Care. 2019;42:2042-2049.
Vantyghem MC, de Koning EJP, Pattou F, Rickels MR. Advances in beta-cell replacement therapy for the treatment of type 1 diabetes. Lancet. 2019;394:1274-1285.
Kent LA, Gill GV, Williams G. Mortality and outcome of patients with brittle diabetes and recurrent ketoacidosis. Lancet. 1994;344:778-781.
International Hypoglycaemia Study Group. Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol. 2019;7:385-396.
Sepulveda E, Poinhos R, Nata G, et al. Differentiating hypoglycemia awareness status from hypoglycemia experience in tools for measuring impaired awareness of hypoglycemia. Diabetes Technol Ther. 2020;22:541-545.
Choudhary P, Amiel SA. Hypoglycaemia in type 1 diabetes: technological treatments, their limitations and the place of psychology. Diabetologia. 2018;61:761-769.
Dunn JT, Choudhary P, Teh MM, et al. The impact of hypoglycaemia awareness status on regional brain responses to acute hypoglycaemia in men with type 1 diabetes. Diabetologia. 2018;61:1676-1687.
Lablanche S, David-Tchouda S, Margier J, et al. Randomised, prospective, medico-economic nationwide french study of islet transplantation in patients with severely unstable type 1 diabetes: the stabilot study protocol. BMJ Open. 2017;7:e013434.